The latest price target for Lipocine (NASDAQ:LPCN) was reported by Cantor Fitzgerald on July 27, 2023. The analyst firm set a price target for $33.00 expecting LPCN to rise to within 12 months (a possible 329.13% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Lipocine (NASDAQ:LPCN) was provided by Cantor Fitzgerald, and Lipocine reiterated their overweight rating.

There is no last upgrade for Lipocine

There is no last downgrade for Lipocine.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lipocine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lipocine was filed on July 27, 2023 so you should expect the next rating to be made available sometime around July 27, 2024.

While ratings are subjective and will change, the latest Lipocine (LPCN) rating was a reiterated with a price target of $0.00 to $33.00. The current price Lipocine (LPCN) is trading at is $7.69, which is within the analyst’s predicted range.